APOL1 polymorphism modulates sphingolipid profile of human podocytes

Area of Science:

• Cell Biology
• Biochemistry
• Nephrology

Background:

• Apolipoprotein L1 (APOL1) wild type (G0) influences sphingolipid metabolism, a key process for lipid rafts.
• APOL1 variants (G1/G2) are associated with kidney disease risk, but their direct impact on podocyte sphingolipid metabolism is unclear.

Purpose of the Study:

• To investigate how APOL1 variants (G1/G2) affect sphingolipid metabolism in human podocytes.
• To determine if APOL1 variants alter sphingolipid profiles within detergent-resistant membranes (DRMs).

Main Methods:

• Overexpression of APOL1 (G0, G1, G2) in human podocytes.
• Analysis of sphingolipid patterns using thin-layer chromatography and mass spectrometry.
• Metabolic labeling with [1-3H]sphingosine and assessment of glycohydrolase activity.

Main Results:

• APOL1 variants (G1/G2) significantly altered sphingolipid profiles in human podocytes, especially within DRMs.
• A notable decrease in globotriaosylceramide, globopentaosylceramide, ceramide, and lactosylceramide was observed with APOL1 variants.
• Glucosylceramide levels were specifically reduced in the DRMs of podocytes expressing APOL1 G1/G2 variants.

Conclusions:

• Altered sphingolipid profiles in human podocytes due to APOL1 variants may contribute to podocyte dysfunction.
• Changes in DRM sphingolipid composition are a key consequence of APOL1 variant expression.
• These findings provide insights into the molecular mechanisms underlying APOL1-associated kidney disease.